Trial Profile
A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2024
Price :
$35
*
At a glance
- Drugs Debamestrocel (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Sponsors Brainstorm Cell Therapeutics
- 10 Apr 2024 Results presented in the Brainstorm Media Release.
- 10 Apr 2024 According to a Brainstorm media release, the company announced peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve journal
- 17 Nov 2023 According to a Brainstorm media release, new analyses from this trial will be presented at the 6th Annual ALS Research Symposium hosted by ALS ONE.